CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Abatacept

Abatacept

Last Updated: October 26, 2006

Result type: Reports

Project Number: SR0084-000

Product Line: Reimbursement Review

Generic Name: Abatacept

Brand Name: Orencia

Manufacturer: Bristol-Myers Squibb Canada

Therapeutic Area: Arthritis, Rheumatoid

Indications: Arthritis, Rheumatoid

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: June 27, 2007

Recommendation Type: List with clinical criteria and/or conditions

Abatacept

Files